2018, Peter Bergman, Akthelia's clinical advisor, received research support from the Swedish Foundation To Prevent Antibiotic Resistance. The foundation's website featured an interview with Peter which can be found here.
-
Febrile neutropenia is a common,
-
Gut barrier Injury and Neutrophil
depletion puts patients at risk for
bacteremia and sepsis -
AKTHELIA'S DRUG CANDIDATE KNOCKS OUT
BACTERAEMIA BY STRENGTHENING
INNATE GUT BARRIER DEFENSES -
eliminating the need for prophylactiC antibiotics
-
reducing risk of serious adverse events,
antimicrobial resistance and
microbiome dysbiosis
Akthelia has been selected as a finalist for the Science 2 Startup event which will be held in Cambridge, Massachusetts in April. This will be an all-day symposium with a keynote speaker, poster sessions, and panel discussions to help facilitate better relationships between PIs / TTOs and investors in the biotech community. https://www.science2startup.com/
A clinical trial performed by a consortium involving Akthelia’s founders has been completed. The trial involved 288 participants and tested one of Akthelia’s actives in combination with traditional antibiotics. The results show that Akthelia’s APIs improved clinical score and other clinical markers of Tuberculosis over using the traditional antibiotics alone. The results have been published in PLOS One (http://www.ncbi.nlm.nih.gov/pubmed/26394045).
Akthelia is very proud to announce that Dr. Stefán Jökull Sveinsson has joined Akthelia’s board of directors. Dr. Sveinsson was Executive Vice President-Research & Development at Actavis for over 15 years where he directed drug development. Prior to that, he directed drug development at Delta and was a professor in Pharmacology at the University of Iceland. After leaving Actavis he has worked as an independent advisor in the pharmaceutical industry.
Akthelia has applied for a patent for a novel class of pharmaceutically active ingredients (APIs) that induce the expression of antibacterial peptides. These APIs are small molecules that activate production of the antibacterial peptides in cell and animal models. Efficacy has been shown against Shigella and Vibrio cholera infections in rabbits.
Jón Ingi Benediktsson has joined Akthelia as General Manager. Jón Ingi has extensive experience in biotech investments. He was the CEO of Líftæknisjóðurinn (MP Bio) from November 2000 – April 2005, then he served as Director for the Akureyri University Research and Innovation Center. From January 2008 he was member of SEED Capital, the largest early stage venture fund in Denmark, life science investment team as Investment Manager and later on as Investment Director, responsible for their overall early stage life science investments. Akthelia is looking forward to having him on board.
MEMBERS OF AKTHELIA MANAGEMENT PLAY MAJOR ROLES AT ANTIBACTERIAL CONFERENCE.
Antibacterial Conference.
Birgitta Agerberth, Director of Medical Microbial Pathogenesis of Akthelia Pharmaceuticals was one of two vice-chairs of the conference and also acted as a Discussion Leader during the session on „Understanding biology through the AMPs“. Guðmundur Hrafn Guðmundsson, Chairman of Akthelia‘s board of directors was a discussion leader during the session on „Regulation of AMP expression“ and presented his work in a poster. The participation of Drs Agerberth and Guðmundsson in the conference further establishes their leading role in the field of antibacterial peptides.